Development of population pharmacokinetics model of isoniazid in Indonesian patients with tuberculosis
Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved..
OBJECTIVES: No population pharmacokinetics (PK) model of isoniazid (INH) has been reported for the Indonesian population with tuberculosis (TB). Therefore, we aimed to develop a population PK model to optimize pharmacotherapy of INH on the basis of therapeutic drug monitoring (TDM) implementation in Indonesian patients with TB.
MATERIALS AND METHODS: INH concentrations, N-acetyltransferase 2 (NAT2) genotypes, and clinical data were collected from Dr. Soetomo General Academic Hospital, Indonesia. A nonlinear mixed-effect model was used to develop and validate the population PK model.
RESULTS: A total of 107 patients with TB (with 153 samples) were involved in this study. A one-compartment model with allometric scaling for bodyweight effect described well the PK of INH. The NAT2 acetylator phenotype significantly affected INH clearance. The mean clearance rates for the rapid, intermediate, and slow NAT2 acetylator phenotypes were 55.9, 37.8, and 17.7 L/h, respectively. Our model was well-validated through visual predictive checks and bootstrapping.
CONCLUSIONS: We established the population PK model for INH in Indonesian patients with TB using the NAT2 acetylator phenotype as a significant covariate. Our Bayesian forecasting model should enable optimization of TB treatment for INH in Indonesian patients with TB.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:117 |
|---|---|
| Enthalten in: |
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases - 117(2022) vom: 15. Apr., Seite 8-14 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Soedarsono, Soedarsono [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antitubercular Agents |
|---|
| Anmerkungen: |
Date Completed 31.03.2022 Date Revised 01.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijid.2022.01.003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM335521010 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335521010 | ||
| 003 | DE-627 | ||
| 005 | 20231225230034.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2022.01.003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1118.xml |
| 035 | |a (DE-627)NLM335521010 | ||
| 035 | |a (NLM)35017103 | ||
| 035 | |a (PII)S1201-9712(22)00004-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Soedarsono, Soedarsono |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Development of population pharmacokinetics model of isoniazid in Indonesian patients with tuberculosis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.03.2022 | ||
| 500 | |a Date Revised 01.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a OBJECTIVES: No population pharmacokinetics (PK) model of isoniazid (INH) has been reported for the Indonesian population with tuberculosis (TB). Therefore, we aimed to develop a population PK model to optimize pharmacotherapy of INH on the basis of therapeutic drug monitoring (TDM) implementation in Indonesian patients with TB | ||
| 520 | |a MATERIALS AND METHODS: INH concentrations, N-acetyltransferase 2 (NAT2) genotypes, and clinical data were collected from Dr. Soetomo General Academic Hospital, Indonesia. A nonlinear mixed-effect model was used to develop and validate the population PK model | ||
| 520 | |a RESULTS: A total of 107 patients with TB (with 153 samples) were involved in this study. A one-compartment model with allometric scaling for bodyweight effect described well the PK of INH. The NAT2 acetylator phenotype significantly affected INH clearance. The mean clearance rates for the rapid, intermediate, and slow NAT2 acetylator phenotypes were 55.9, 37.8, and 17.7 L/h, respectively. Our model was well-validated through visual predictive checks and bootstrapping | ||
| 520 | |a CONCLUSIONS: We established the population PK model for INH in Indonesian patients with TB using the NAT2 acetylator phenotype as a significant covariate. Our Bayesian forecasting model should enable optimization of TB treatment for INH in Indonesian patients with TB | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Indonesia | |
| 650 | 4 | |a Isoniazid | |
| 650 | 4 | |a Population Pharmacokinetics | |
| 650 | 4 | |a Therapeutic Drug Monitoring | |
| 650 | 4 | |a Tuberculosis | |
| 650 | 7 | |a Antitubercular Agents |2 NLM | |
| 650 | 7 | |a Arylamine N-Acetyltransferase |2 NLM | |
| 650 | 7 | |a EC 2.3.1.5 |2 NLM | |
| 650 | 7 | |a NAT2 protein, human |2 NLM | |
| 650 | 7 | |a EC 2.3.1.5 |2 NLM | |
| 650 | 7 | |a Isoniazid |2 NLM | |
| 650 | 7 | |a V83O1VOZ8L |2 NLM | |
| 700 | 1 | |a Jayanti, Rannissa Puspita |e verfasserin |4 aut | |
| 700 | 1 | |a Mertaniasih, Ni Made |e verfasserin |4 aut | |
| 700 | 1 | |a Kusmiati, Tutik |e verfasserin |4 aut | |
| 700 | 1 | |a Permatasari, Ariani |e verfasserin |4 aut | |
| 700 | 1 | |a Indrawanto, Dwi Wahyu |e verfasserin |4 aut | |
| 700 | 1 | |a Charisma, Anita Nur |e verfasserin |4 aut | |
| 700 | 1 | |a Yuliwulandari, Rika |e verfasserin |4 aut | |
| 700 | 1 | |a Long, Nguyen Phuoc |e verfasserin |4 aut | |
| 700 | 1 | |a Choi, Young-Kyung |e verfasserin |4 aut | |
| 700 | 1 | |a Hoa, Pham Quang |e verfasserin |4 aut | |
| 700 | 1 | |a Hoa, Pham Vinh |e verfasserin |4 aut | |
| 700 | 1 | |a Cho, Yong-Soon |e verfasserin |4 aut | |
| 700 | 1 | |a Shin, Jae-Gook |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases |d 1998 |g 117(2022) vom: 15. Apr., Seite 8-14 |w (DE-627)NLM094730857 |x 1878-3511 |7 nnns |
| 773 | 1 | 8 | |g volume:117 |g year:2022 |g day:15 |g month:04 |g pages:8-14 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijid.2022.01.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 117 |j 2022 |b 15 |c 04 |h 8-14 | ||